Introduction {#s1}
============

*Plasmodium vivax* is the second most prevalent malarial pathogen, with a wider geographical distribution than *P. falciparum,* suggested to be a risk of malaria infection for 2.5 billion people ([@bib15]). According to the WHO report (2017), an estimated 8.5 million new clinical cases of *P. vivax* was reported in 2016 globally. Despite its high prevalence in many malaria endemic countries, *P. vivax* research is restricted to few laboratories and limited progress has been made ([@bib2]). Notwithstanding, the FDA recently approved tafenoquine as a radical cure therapy and prophylactic for *P. vivax* malaria infection ([@bib12]). This is a significant advance as tafenoquine is administered as a single dose regimen, which is a very important improvement for patient compliance when compared to the lengthy 14-day drug regimen of its closely related predecessor primaquine. However, tafenoquine is only approved for patients over the age of 16 and, like primaquine, it cannot be administered to patients who have glucose-6-phosphate dehydrogenase (G6PD) deficiency, a common genetic disorder in malaria endemic countries, due to serious adverse side-effects and life-threatening drug-induced hemolysis ([@bib33]; [@bib18]). Therefore, new drugs are critically needed to enable malaria elimination.

Malaria transmission begins when uni-nucleated sporozoites are transmitted by mosquito bite, reach the liver and invade hepatocytes within which they transform into multi-nucleated hepatic schizonts. Mature schizonts release merozoites that infect red blood cells (RBCs) and lead to the onset of clinical symptoms associated with malaria. Remarkably, sporozoites of *P. vivax, P. ovale and P. cynomolgi* can generate latent forms known as hypnozoites ([@bib25]). Hypnozoites, triggered by unknown signals, periodically activate several weeks (or even months) after the initial infection to cause malaria relapse ([@bib33]; [@bib28]). Activation of hypnozoites was suggested to be responsible for 90% of the global clinical burden associated with relapsing malaria ([@bib1]). Despite recent advances in development of models to study hepatic relapses in vitro ([@bib11]; [@bib14]; [@bib26]) and in vivo ([@bib20]; [@bib17]), the quest for novel radical cure therapies is stymied by our poor understanding of the molecular determinants of hypnozoite persistence and activation.

The simian relapsing malaria parasite *P. cynomolgi (Pcy)*---closely related to the *P. vivax* human malaria parasite---has been crucial to our current understanding of the hypnozoite biology ([@bib11]; [@bib16]; [@bib8]; [@bib32]) and the discovery of novel liver-stage active compounds ([@bib34]; [@bib35]) and anti-relapse drug candidates ([@bib6]). Here, using in vitro and in vivo liver stage infection models, we demonstrated that LISP2 is a molecular marker of initiation of liver-stage development in relapsing malaria parasites. As proof of concept, using known drugs that have differential effect on hypnozoites, we showed that the LISP2 marker could assess anti-relapse drug activities in vitro.

Results {#s2}
=======

LISP2 is an early marker of parasite development in the liver {#s2-1}
-------------------------------------------------------------

To increase our understanding of the molecular mechanisms that may be underlying the physiological regulation of hypnozoite persistence and activation, we and others have recently carried out comparative transcriptomics analysis of persistent, non-replicating and replicating liver-stages of the *P. cynomolgi* parasite ([@bib32]; [@bib9]). Searching for potential markers specific to dormancy in our transcriptomic dataset has proven to be difficult because hypnozoites appear to globally suppress transcription and very few genes are specifically up-regulated in hypnozoites ([@bib32]). We reasoned that markers of hypnozoite activation and schizogony might be easier to identify as we speculated that they would be significantly enriched in large replicating parasites albeit detectable at least in a fraction of smaller parasites that might be activating hypnozoites or earliest developing forms. Looking for genes with such an expression pattern, we looked for genes that were detected above \>10 FPKM (Fragments Per Kilobase Per Million) in hypnozoite (727 genes) and that were in the top 5% genes expressed in schizonts (134 genes). Amongst the seven genes fulfilling these criteria (most of them were encoding hypothetical proteins; see [Supplementary file 1](#supp1){ref-type="supplementary-material"}), we identified the gene PcyM_0307500, the *P. cynomolgi* ortholog of the rodent *Plasmodium berghei* Liver-Specific Protein 2 (LISP2) ([@bib24]). In *P. cynomolgi,* LISP2 is dramatically upregulated (over 72-fold, p-value 0.0009) in replicating schizonts but, nonetheless, detectable at significant level (average FPKM 12) in hypnozoites. A similar expression pattern was reported for the *P. vivax* LISP2 (PVP01_0304700) in the recently published liver stage transcriptome ([@bib14]). PVP01_0304700 was found to be highly expressed in (\>150, Transcripts per million, TPM) mix population (mixture of all hepatic stages), whereas it was significantly detected (\>25 TPM) in hypnozoite enriched samples above threshold (25 TPM).

LISP2 protein is 2038 amino-acids (aa) and 2519 aa long in *P. cynomolgi* and *P. vivax*, with an N-terminal signal peptide and a conserved C-terminal 6-cysteine domain (6-cys) found in a family of apicomplexan-specific proteins which are mostly surface proteins ([@bib3]; [@bib31]). To determine the subcellular localization of LISP2 in relapsing malaria parasites, we raised antibodies against the conserved 6-cys domain for both predicted proteins encoded by the *P. cynomolgi* (PcyM_0307500) and *P. vivax* (PVP01_0304700/PVX000975) LISP2 genes ([Figure 1A](#fig1){ref-type="fig"}). We confirmed the specificity of both *P. cynomolgi* and *P. vivax* LISP2 antibodies against the recombinant antigen by western blot ([Figure 1---figure supplement 1A and B](#fig1s1){ref-type="fig"}). Cultivated simian hepatocytes infected with *P. cynomolgi* B-strain sporozoites (spz) were then analyzed in immunofluorescence assay (IFA) with anti-LISP2 and anti-HSP70 antibodies to monitor LISP2 expression over time. *P. cynomolgi* infected simian hepatocytes from three different macaques were maintained in vitro from day 1 to day 12 in monolayer ([Figure 1B](#fig1){ref-type="fig"}) and switched to the previously reported long term in vitro sandwich culture model ([@bib11]) from day 13 to day 21 ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). LISP2 immunostaining was only observed starting at day 3 in a characteristic crescent-shape asymmetrically located on one side of the early developing liver parasites, or trophozoites (LISP2+). By day 4, LISP2 protein is distributed all around the peripheral membrane in a circular pattern around the parasites that were all very clearly multinucleated (\>3 nuclei). By day 5 in larger schizonts, LISP2 appears to accumulate in peripheral vacuolar membrane structures that were not labeled by DAPI or HSP70 antibody (LISP2++). We observed those vacuoles from day 6 onwards, as the parasites mature and grow to larger schizonts. During this intensive parasite growth phase (Day 4 to Day 10), LISP2 staining was observed in the same vacuolar and peripheral membrane pattern (LISP2++) in multinucleated parasites ([Figure 1B](#fig1){ref-type="fig"}). Although the resolution of DAPI staining does not allow for an accurate count of the number of nuclei, LISP2+ parasites generally appear to have few nuclei (see representative images on [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). The HSP70 protein is detected during all the *Plasmodium* liver life-cycle stages and HSP70 immunostaining is seen for all parasites from day 1 and throughout the entire 21 days period. We independently confirmed this expression pattern at the RNA level in Fluorescent In Situ Hybridization (FISH) experiments in *P. cynomolgi* cultures. Indeed, the LISP2 transcript is robustly expressed in schizonts but more weakly in a subset of smaller parasites ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}).

![LISP2 marks the beginning of hepatic stage development.\
(**A**) Schematic structure of the LISP2 gene showing the N-terminal signal peptide, 6-cys domain and epitope (highlighted in black) used as immunogen to raise antibodies against *P. cynomolgi* and *P. vivax* LISP2 protein (**B**) Immunofluorescence assay, IFA of *P. cynomolgi* liver stage parasites in infected simian primary hepatocytes showing liver stage development from day 1 to day 12 post-infection visualized with DAPI for DNA content (blue), a polyclonal antibody specific for *P. cynomolgi* HSP70 protein (green) and a monoclonal antibody specific for *P. cynomolgi* LISP2 protein (red); Scale bar, 35 µm. From day 3 onwards, LISP2 staining observed in a crescent shape asymmetrically located on one side of earliest developing parasites (LISP2+). By day 5, LISP2 accumulates in peripheral vacuolar membrane structures in multinucleate schizonts and does not co-localize with DAPI or HSP70 (LISP2++).](elife-43362-fig1){#fig1}

Assessment of LISP2 expression in *P. vivax* liver stages {#s2-2}
---------------------------------------------------------

We next determined the LISP2 expression in vivo in human liver chimeric mice (huHep mice) infected with the *P. vivax* human parasite ([@bib20]). The huHep mice were inoculated with 1 × 10^6^ of *P. vivax* sporozoites. *P. vivax* infected mice were sacrificed at days 3, 5, 8 and 18 and liver tissues were examined for the presence of hepatic stages by performing IFA. Liver stages were assessed using *P. vivax* antibodies against LISP2 and UIS4 (upregulated in infectious sporozoite 4) proteins. Similar to the in vitro observations with *P. cynomolgi* parasites, LISP2 expression is first observed at days 3 post-infection in *P. vivax* with an identical crescent staining located at one side of the membrane. During the course of development from day 3 to day 18, we observed a large fraction of non-replicating small parasites (hypnozoites) that were devoid of LISP2 expression in *P. vivax*. At each time point (days 3, 5, 8 and 18), LISP2- hypnozoite and LISP2+ trophozoite were of similar size ranges. As reported earlier, UIS4 protein accumulated in a characteristic prominence in established mature hypnozoites ([@bib20]) as well as in LISP2+ trophozoites while in mature schizonts the entire parasitophorous vacuole membrane (PVM) were stained ([Figure 2A](#fig2){ref-type="fig"}). Interestingly, we also observed that UIS4 and LISP2 proteins co-localized at the PVM prominence in LISP2+ trophozoites at all time-points ([Figure 2B](#fig2){ref-type="fig"}). We could not perform UIS4 and LISP2 co-staining in *P. cynomolgi* as both antibodies were made in same species, notwithstanding we could demonstrate the presence of UIS4 PVM prominence in established hypnozoites in *P. cynomolgi* ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Collectively, the above data from in vitro and in vivo suggests that LISP2 is expressed in early developing liver stage parasites and represents a marker for initiation of liver stage schizogony in relapsing malaria species.

![Evaluation of LISP2 expression in *P. vivax* infected huHep mice.\
(**A**) Hepatic stages of *P. vivax* infected huHep mice were stained with DAPI (blue), a monoclonal antibody specific for *P. vivax* LISP2 protein (red) and a monoclonal antibody specific for *P. vivax* UIS4 protein (green). Representative images of LISP2-, LISP2+ and LISP2++ parasites at days 3, 5, 8 and 18 post-sporozoite infection are shown. (**B**) Day 8 LISP2+ trophozoite visualized for LISP2 (red) and UIS4 (green). The area in the yellow box is highlighted to show partial overlap of LISP2 and UIS4 localization at or near PVM prominence. Scale bar, 25 µm.](elife-43362-fig2){#fig2}

LISP2 expression differentiates dormant hypnozoites from developing liver stages {#s2-3}
--------------------------------------------------------------------------------

Because LISP2 expression was first detected in day 3 in early developing parasites of small size, we reasoned that LISP2 antibodies might distinguish the persistent hypnozoites population from those similarly sized earliest developing trophozoites. To visualize and quantify the different hepatic stages using LISP2 expression, we first carried out LISP2 immunostaining analysis at day 6 post-infection. Our results revealed the presence of three distinct populations of liver stage parasites. In total, 23% of the day 6 liver stage parasites robustly expressed the LISP2 protein (LISP2++), whereas the vast majority of the liver stage parasites (73%) remained smaller, uni-nucleated, and did not react with the LISP2 monoclonal antibodies (LISP2-). In addition to these large multinucleated parasites, we also observed a small fraction of LISP2 positive trophozoites (4%) with a characteristic crescent-shape LISP2 staining pattern (LISP2+) ([Figure 3A](#fig3){ref-type="fig"}).

![LISP2 expression distinguishes hypnozoites population from early developing liver stages.\
(**A**) Immunofluorescence assay (IFA) of *P. cynomolgi* liver stage parasites in simian primary hepatocytes 6 days after sporozoite inoculation visualized with DAPI for DNA content (blue), a polyclonal antibody specific for *P. cynomolgi* HSP70 protein (green), a monoclonal antibody specific for *P. cynomolgi* LISP2 protein (red). Scale bar, 35 µm. Merged IFA image showing *P. cynomolgi* three distinct hepatic parasite populations at day 6 post-infection: LISP2- (green), LISP2+ (weak red crescent staining) and LISP2++ (strong red peripheral and vacuolar staining). (**B**) Growth kinetic of three distinct *P. cynomolgi* parasite populations, dormant hypnozoites (LISP2-), early developing trophozoite (LISP2+) and growing schizonts (LISP2++). Data for size (the diameter of the parasite) are from three independent experiments. The cumulative number of cells measured in three biological experiments for each time point from day 1 to day 21 was ≥90. (**C**) *P. cynomolgi* hepatic stages stained with LISP2 and PV1 (parasitophorous vacuole 1), a marker of PV at day 6 post-sporozoite infection. LISP2+ trophozoite and LISP2++ schizonts showed co-localization of LISP2 and PV1. In contrast, hypnozoites were devoid of any signal from anti-Pc LISP2 and were stained only by anti-Pc PV1. Scale bar, 25 µm. The source data is available for [Figure 3B](#fig3){ref-type="fig"} (see source data file [Figure 3](#fig3){ref-type="fig"}).\
10.7554/eLife.43362.015Figure 3---source data 1.Growth kinetics data of different liver populations for 21 days post-infection.](elife-43362-fig3){#fig3}

Next, we set out to quantify the parasite growth kinetics and daily measured the liver stage size for each of these three parasite populations (LISP2-, LISP2+ and LISP2++) ([Figure 3B](#fig3){ref-type="fig"}). In the first 8--9 days, persistent LISP2- hypnozoites increase in size from about 1 μm diameter to reach a plateau at about 6 μm diameter on average. Similarly, persistent *P. vivax* hypnozoites have been reported to undergo a slight growth phase *in vivo* ([@bib20]). In sharp contrast, the size of LISP2+ trophozoites does not change over time and remained constant from day 3 to day 21 at a median size of 6.9 μm (5th to 95th percentile; 6.3 and 7.3) in diameter ([Figure 3B](#fig3){ref-type="fig"}). Thus, remarkably, from day 7 to day 8 onwards, LISP2- hypnozoites and LISP2+ trophozoites were indistinguishable by size. As expected, developing LISP2++ liver stage schizonts were significantly bigger at day 4 with a median diameter of 9.4 μm (5th to 95th percentile; 6.9 and 15.1) and continue to grow to reach a plateau by day 10 with a median size of about 21.6 μm (5th to 95th percentile; 9.1 and 49) in diameter for mature schizonts. Collectively, the LISP2 expression pattern suggested that LISP2+ parasites may be appearing continuously throughout the culture period and develop into LISP2++ maturing schizonts ranging from 7 to 8 µm up to 49 µm in diameter.

We next wanted to quantify the fraction of parasites observed daily for each of the three populations (LISP2-, LISP2+ and LISP2++) over the 21-day observation period. The results of experiments carried out with three independent batches of *P. cynomolgi* sporozoites and three independent sources of simian hepatocytes are reported in [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}. Using LISP2 and HSP70 antibodies, we monitored the proportion of different hepatic forms of the parasite from day 1 to day 21 ([Figure 3---figure supplement 1A and B](#fig3s1){ref-type="fig"}). The total number of parasites counted in each day for 3 hepatocyte donors is reported in the graphs in [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}. As expected the total number of parasites decreased over time as they grew to mature schizonts and merosomes. In the first 2 days following the sporozoite infection, we detected only small LISP2- parasites positively stained with the HSP70 antibody. These LISP2- uni-nucleated parasites persisted as hypnozoites until day 21 and constitute the majority (≥65%) of the parasite liver stages from day 3 onwards. A small fraction (≤10%) of LISP2+ trophozoites first appeared on day 3 to reach a maximum proportion of 15--20% by day 4. From Day 5 onwards, the fraction of LISP2+ parasites remained small (≤5%) but steady. A small number of LISP2++ parasites (≤3%) was first detected around day 4 and the proportion of LISP2++ developing parasites increased to about 20% from days 5 to day 6 onwards ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).

We further demonstrated that these LISP2- parasites were viable parasites as they were labeled with the transcriptional activity marker H3K9ac ([@bib32]; [@bib13]). Notwithstanding, as previously shown ([@bib32]), schizonts were remarkably more transcriptionally active than hypnozoites as demonstrated by the much larger number of H3K9ac positive structures ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"} and [Video 1](#video1){ref-type="video"}).

###### Co-localization of H3K9ac and LISP2.

Reconstructed 3-D movie of schizonts using de-convoluted Z stack images co-stained with DAPI (blue color), H3K9ac (green color) and LISP2 (red color).

10.7554/eLife.43362.016

Given the fact that LISP2 staining was first observed in characteristic crescent shape on PVM in LISP2+ parasites, we hypothesized that it could be a PV resident protein. To investigate the localization of LISP2 in PV, co-localization experiments were performed using antibodies developed against the *P. cynomolgi* ortholog of *P. falciparum* PV resident proteins; PV1 (parasitophorous vacuolar protein 1; PcyM_0933600). PV1 was previously reported to be resident protein of PV in blood stages ([@bib7]). Further demonstrating that LISP2- stained parasites are not artifact staining but bona fide constructive infections, parasites were stained positively with PV1 and similarly to the staining pattern observed in blood stages PV1 antibodies specifically highlight the circumference of the parasitophorous vacuole ([@bib23]) ([Figure 3c](#fig3){ref-type="fig"}). Interestingly, early in development the crescent of LISP2+ parasites overlapped with PV1 staining. Importantly, we observed that both LISP2- hypnozoites and LISP2+ trophozoites show identical PV1 staining patterns. Strikingly, PV1 protein co-localizes with LISP2 in LISP2++ schizonts, which suggests that LISP2 could be a PV resident protein ([Figure 3c](#fig3){ref-type="fig"}, [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"} and [Videos 2](#video2){ref-type="video"}, [3](#video3){ref-type="video"}, [4](#video4){ref-type="video"} and [5](#video5){ref-type="video"}). Taken together, we show that LISP2- hypnozoites and the earliest developing form, LISP2+ trophozoites, are of similar size range, have a functional PV as they were stained positively for PV proteins, PV1 or UIS4 and could be distinguished on the basis of LISP2 expression.

###### Co-localization of PV1 and LISP2 at parasitophorous vacuole.

Day 6 infected hepatocytes co-stained with DAPI (blue; see [Video 3](#video3){ref-type="video"}), PV1 (green; see [Video 4](#video4){ref-type="video"}) and LISP2 (red; see [Video 5](#video5){ref-type="video"}). 30--40 stacks of images were acquired with 100X objective lens with Z-step size of 0.3 μm. Three-Dimensional movies of the merged channel (in yellow color) and individual channels reconstructed using deconvoluted z-stack images are shown.

10.7554/eLife.43362.017

###### Three-dimensional movie of the day 6 infected hepatocytes stained with DAPI (blue).

Each movie is made from 30 to 40 stacks of images acquired with 100X objective lens with Z-step size of 0.3 μm.

10.7554/eLife.43362.018

###### Three-dimensional movie of the day 6 infected hepatocytes stained with PV1 (green).

Each movie is made from 30 to 40 stacks of images acquired with 100X objective lens with Z-step size of 0.3 μm.

10.7554/eLife.43362.019

###### Three-dimensional movie of the day 6 infected hepatocytes stained with LISP2 (red).

Each movie is made from 30 to 40 stacks of images acquired with 100X objective lens with Z-step size of 0.3 μm.

10.7554/eLife.43362.020

LISP2 expression correlates with drug sensitivity to prophylactic drugs {#s2-4}
-----------------------------------------------------------------------

Based on the above results, we hypothesized that LISP2 expression may discriminate developing forms from persistent hypnozoites that do not react with LISP2 antibodies and could serve as a molecular marker to predict the anti-relapse drug effect in vitro assays. The most salient pharmacological features of dormant hypnozoites are: (1) susceptibility to 8-aminoquinolines compounds like tafenoquine (TQ) ([@bib6]) and, (2) resistance to atovaquone (ATQ) ([@bib5]) and PI4K inhibitors ([@bib34]; [@bib35]). We thus set out to determine the susceptibility of liver stage parasites with (LISP2+, LISP2++) and without LISP2 (LISP2-) exposed to three drugs TQ, ATQ, and the *Plasmodium* PI4K inhibitor KDU691 ([@bib19]). For each three drugs, we first carried out drug assays at single concentration that we have previously shown to be effective in *P. cynomolgi* infected hepatocytes ([@bib34]; [@bib35]; [@bib10]). Importantly, all drugs were found to be non-cytotoxic to simian hepatocytes up to 10 μM ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Parasites were exposed to drugs starting at day 4 through day 8 post-infection in a radical cure mode assay and parasite counts were carried out at day 8, day 15 and day 21 ([Figure 4A](#fig4){ref-type="fig"}).

![LISP2 negative parasites are refractory to PI4K inhibition but sensitive to 8-aminoquinoline drugs.\
(**A**) Simian primary hepatocytes infected with *P. cynomolgi* parasites were exposed to ATQ (0.25 µM), KDU691 (0.5 µM) and TQ (1 µM) from day 4 to day 8 post-infection. The effects of drug treatments were compared to untreated control (DMSO) at day 8, day 15 and day 21 post-infection; p value is assessed by statistical one--tailed t test with \*p\<0.05 and\*\*0.01, respectively. (**B**) Blue bars show drug effects on persistent LISP2- hypnozoites. (**C**) Red bars represent drug effects on LISP2-positive parasites. (**D**) Dose response curve for ATQ, KDU691 and TQ are shown. The blue curves represent drug activity against hypnozoite (LISP2-) and red curves show activity against LISP2 positive parasites. The IC50 (inhibitory concentration) of KDU691 against LISP2- hypnozoites and LISP2 expressing parasites were 1.8 µM and 0.13 µM. The IC50 of ATQ for LISP2- and LISP2 expressing parasites were 0.48 µM and 0.036 µM, respectively. The graph bar in [Figure 4B and C](#fig4){ref-type="fig"} represent mean with standard deviation (s.d) from five technical replicates in two independent biological assays, whereas in [Figure 4D](#fig4){ref-type="fig"} from three independent biological assays. The source data is available for [Figure 4](#fig4){ref-type="fig"} (see source data file [Figure 4](#fig4){ref-type="fig"}).\
10.7554/eLife.43362.024Figure 4---source data 1.In vitro radical cure mode assay for liver stage.](elife-43362-fig4){#fig4}

At day 8, as expected, LISP2- hypnozoites were not sensitive to ATQ (0.25 µM) and KDU691 (0.5 µM) treatments ([Figure 4B](#fig4){ref-type="fig"}). In contrast, the 8-aminoquinoline, TQ (1 µM) was active against dormant LISP2- hypnozoites at all three time-points. ([Figure 4B and C](#fig4){ref-type="fig"}). In addition, compared to DMSO, TQ reduced 70% (p value 0.0003), 78% (p value 0.0009) and 83% (p value 0.04) of all hepatic forms at day 8, day 15 and day 21, respectively.

ATQ and KDU691 eliminated 55% (p value is 0.01) and 84% (p value is 0.005) of LISP2 expressing hepatic stages at day 8. Importantly, by day 15 and day 21 ATQ and KDU691 treated cultures displayed a number of LISP2 expressing parasites comparable to untreated controls (DMSO) ([Figure 4C](#fig4){ref-type="fig"}). This, together with the steady decrease of the number of LISP2- hypnozoites, strongly suggests that persistent hypnozoites (LISP2-) re-activated between day 8 and day 21 to produce LISP2+ trophozoites which growth was unhindered after the drugs were washed away to develop into new replicating schizonts (LISP2++). In contrast, because TQ killed LISP2- hypnozoites at day 8, the drug effects of TQ was borne out at day 15 and day 21 with \>90% significant reduction from control of TQ (p value for TQ at day 15 is 0.001), respectively ([Figure 4B](#fig4){ref-type="fig"}).

We confirmed the above observations in dose response experiments by assessing the number of parasites that survived in the culture exposed to eight different doses of ATQ, TQ and KDU691 from day 4 to day 8 with concentration ranging from 10 µM to 13 nM. The radical cure assay was performed in triplicates in three independent experiments. Our assay showed that when compared to LISP2 negative parasites, LISP2 expressing parasites were respectively 13 and 14 fold more susceptible to ATQ and KDU691 ([Figure 4D](#fig4){ref-type="fig"}). In contrast, TQ displayed similar activity against LISP2 expressing parasites and LISP2-negative parasites. Thus LISP2- parasites fulfilled the pharmacological criteria for persistent dormant hypnozoites, namely that they are susceptible to 8-aminoquinolines but phenotypically resistant to atovaquone and PI4K inhibitors.

Discussion {#s3}
==========

The discovery of novel *P. vivax* radical cure drugs, defined as the prevention of relapse and complete elimination of all liver stages of the malaria parasite including the dormant persistent hypnozoites, remains a considerable challenge ([@bib6]). Anti-malarial drug discovery efforts against established hypnozoites and thus preventing relapse is hampered by numerous roadblocks, including lack of high-throughput screening assays that can predict relapse. Most importantly, drug development is hindered by lack of tractable markers that can assess hypnozoite reactivation and monitor the therapeutic efficacy of anti-relapse compounds. The data presented here, and graphically summarized in [Figure 5](#fig5){ref-type="fig"} suggest that the LISP2 protein expression could be a powerful tool to distinguish dormant hypnozoites from activated hypnozoites that differentiated to developing forms in relapse drug assays.

![Schematic model to distinguish hypnozoites from other liver stages based on PI4K drug susceptibility.\
Malaria liver stage infection begins when infective sporozoites injected by mosquitoes invade host hepatocytes. Within hepatocytes, sporozoites transform into hepatic schizonts for 7--9 days and subsequently, mature schizonts burst and release pathogenic merozoites into blood circulation ([@bib25]). Sporozoite transformation into early liver stage development coincides with LISP2 expression. LISP2 expression marks the beginning of liver stage development at day 3 and its expression increases as liver stage progresses into complete maturation. Sporozoites of relapsing malaria species such as *P. vivax* and *P. cynomolgi* can generate dormant hypnozoites ([@bib33]). LISP2- Hz exhibits UIS4 prominence on PVM (shown in green) and grows till day 5 and remains persistent and unchanged from day 5 onwards. LISP2 +Tz display crescent staining pattern (shown in red) which colocalizes with UIS4 protein on PVM. Beyond day 6 post-sporozoite infection, both LISP2- Hz and LISP2+ Tz have identical size and can only be discriminated on the basis of susceptibility to PI4K inhibitor. The shaded areas (in orange) represent the parasite that can be eliminated by both PI4K inhibitors and 8-aminoquinoline drugs. The non-shaded area in the model represents only LISP2- Hz which is resistant to PI4K and can be eliminated only by 8-aminoquinoline drugs. List of supplemental tables.](elife-43362-fig5){#fig5}

Using LISP2 antibodies, we characterized the development of *P. cynomolgi* liver stages in long-term in vitro hepatic cultures. We show that LISP2 is first detected in a characteristic crescent-shape pattern in a subset of small parasites (LISP2+) at day 3 post sporozoite infection, suggesting that LISP2 expression marks the beginning of liver stage development. From day 4 to days 9--10, LISP2 expression increases as parasites mature and grow, and LISP2 distribution drastically expands throughout the parasite membrane and cytosolic vacuoles (LISP2++). The cellular function of these previously reported vacuoles ([@bib30]) is unclear but it has been proposed that this is the cellular compartment in which LISP2 6-cys domain is cleaved and mediates LISP2 N-terminal region export to the hepatocyte cytosol through its signal peptide ([@bib24]). Throughout the 21-day period, we found that a significant proportion of persistent small parasites do not express LISP2 (LISP2-). This LISP2 pattern of developmental expression in liver-stages is fully recapitulated in vivo in the liver of *P. vivax* infected human-chimeric liver mice. We also observed that in early developing parasites (LISP2+ trophozoites), UIS4 and LISP2 co-localize at the previously reported *P. vivax* parasitophorous vacuole membrane (PVM) prominence which was proposed to play a crucial role in the biogenesis and initial development of liver stages ([@bib20]). Importantly, LISP2- hypnozoites and LISP2+ trophozoites appear as two different subpopulations of parasites which are of similar size range and both exhibit the UIS4-prominence characteristic of hypnozoites ([@bib20]). Although the UIS4 prominence was initially regarded as a marker of established *P. vivax* hypnozoites, recent reports have shown that it is also present in small developing forms ([@bib14]). We could confirm these observations in *P. cynomolgi* parasites and further establish that the presence of LISP2 in the UIS4 prominence uniquely distinguishes the early trophozoites from the similarly sized population of established hypnozoites that remain LISP2 negative.

In *P. cynomolgi* liver stages we found that the PV protein PV1 ([@bib21]), localizes to the parasitophorous vacuole, which is a critical interface that separates parasite from host hepatocyte cytoplasm ([@bib22]). Interestingly, we found that LISP2 and PV1 proteins extensively co-localize throughout schizogony, from early developing trophozoites (LISP2+) to late schizonts (LISP2++). PV1 interacts with the export machinery required for the trafficking of *Plasmodium* proteins across PVM to infected erythrocytes during blood stages ([@bib21]) and further functional studies will be required to determine whether LISP2 and PV1 play similar roles in liver stages.

In both, in vitro P. cynomolgi culture and in vivo P. vivax model, we observe LISP2+ trophozoites throughout the time course of our studies. Although we cannot entirely rule out that some of the LISP2+ trophozoites observed are developmentally arrested forms, our data showing (1), active transcription with positive H3K9 staining and (2), the emergence of LISP2+ trophozoites after prophylactic drug treatments, strongly suggest that LISP2+ trophozoites result from hypnozoite activation or relapse. Given the large difference in the inoculum used in our experimental models it is however not clear how the observations reported above relate to clinical malaria relapse rates. Indeed, it is well known that the size of the sporozoites inoculum critically influences the relapse rate observed in simian *P. cynomolgi* malaria ([@bib27]).

One limitation of our study is that we could not monitor LISP2 expression in real-time at the cellular level to unambiguously establish the progressive transition from LISP2- persistent hypnozoites, to LISP2+ trophozoites. Nonetheless, the kinetics of LISP2 expression in vitro (*P. cynomolgi*) and in vivo (*P. vivax*) suggests that LISP2 protein expression is an early event of liver-stage development. Genetic engineering of GFP-expressing parasites reporting the protein localization of LISP2 over time will more firmly establish this developmental sequence and it will help to better delineate the transition from activating hypnozoite to early schizont.

Finally, we show that in *P. cynomolgi* infected hepatocytes, the radical cure drug TQ was potently active on all hepatic stages irrespective of LISP2 expression. In sharp contrast KDU691, a selective inhibitor of the PI4K enzyme, potently clears LISP2 positive (LISP2+ and LISP2++) parasites, but is inactive on persistent LISP2-negative (LISP2-) parasites.

Taken together our data show that the LISP2- parasites display the morphological characteristics and the pharmacological susceptibility profile---sensitivity to 8-aminoquinoline drugs and phenotypic resistance to the prophylactic drug KDU691---of dormant hypnozoites. LISP2 expression closely coincides with the beginning of liver-stage development and is a marker of malaria relapse. These findings will enable the design of novel in vitro assays that directly measure the anti-relapse drug effects in vitro by measuring and following LISP2 activation. Finally, and importantly, our study provides an additional molecular feature to our definition of *Plasmodium* hypnozoites, now defined as small, uni-nuclear persistent hepatic parasites with a UIS4-prominence lacking the LISP2 protein.

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                               Designation                                             Source or reference                                                    Identifiers        Additional\
  (species) or\                                                                                                                                                                                 information
  resource                                                                                                                                                                                      
  ------------------------------------------- ------------------------------------------------------- ---------------------------------------------------------------------- ------------------ -------------------------------------------------------------
  Biological sample (*Macaca mulatta*)        Primary simian hepatocytes                              Biomedical Primate Research Centre, Netherlands                                           Freshly isolated from Macaca mulatta,

  Biological sample (*Macaca fascicularis*)   Primary simian hepatocytes                              SingHealth, Singapore                                                                     Freshly isolated from Macaca fascicularis

  Biological sample (*P. cynomolgi*)          sporozoites                                             Armed forces research institute of medical sciences (AFRIMS) Bangkok                      *Anopheles dirus* mosquito infected with *P. cynomolgi*

  Biological\                                 sporozoites                                             Biomedical Primate Research Centre, Netherlands                                           *Anopheles stephensi* mosquito infected with *P. cynomolgi*
  sample (*P. cynomolgi*)                                                                                                                                                                       

  Biological sample (*P. vivax*)              sporozoites                                             Mahidol University                                                                        *Anopheles dirus* mosquito infected with *P. vivax*

  Antibody                                    Mouse anti-LISP2 antibody (monoclonal)                  this paper                                                                                synthesized by genscript; IFA (1:500)

  Antibody                                    Rabbit anti-PV1 antibody\                               this paper                                                                                synthesized by genscript; IFA (1:500)
                                              (polyclonal)                                                                                                                                      

  Antibody                                    Rabbit anti-HSP70 antibody (polyclonal)                 this paper                                                                                synthesized by genscript; IFA (1:2000)

  Antibody                                    Rabbit anti-H3K9ac\                                     Abcam,                                                                 ab177177           IFA (1:1000)
                                              antibody (monoclonal)                                                                                                                             

  Antibody                                    Alexa 488-conjugated goat anti-rabbit immunoglobulin\   Invitrogen                                                             11034              IFA (1:4000)
                                              (polyclonal)                                                                                                                                      

  Antibody                                    Alexa 594-conjugated goat anti-mouse immunoglobulin\    Invitrogen                                                             11032              IFA (1:5000)
                                              (polyclonal)                                                                                                                                      

  Sequence-\                                  RNA FISH probes                                         this paper                                                                                Synthesized by Advanced Cell Diagnostics
  based reagent                                                                                                                                                                                 

  Commercial assay or kit                     CCK-8 kit                                               Sigma                                                                  96992 100TESTS-F   

  Chemical compound, drug                     KDU691                                                  Novartis internal chemical library                                                        Synthesized by Novartis

  Chemical compound, drug                     Atovaquone (ATQ)                                        Novartis internal chemical library                                                        Synthesized by Novartis

  Chemical compound, drug                     Tafenoquine (TQ)                                        Novartis internal chemical library                                                        Synthesized by Novartis

  Chemical compound, drug                     DMSO                                                    Sigma                                                                  D8418              
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Ethics statement {#s4-1}
----------------

Nonhuman primates were used because no other models (in vitro or in vivo) were suitable for the aims of this project. NHP were used at the Biomedical Primate Research Centre (BPRC), The Netherlands, Novartis Laboratory of Large Animal Services, New Jersey, U.S.A., (Novartis-LAS), SingHealth, Singapore, and The Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand (AFRIMS).

The local independent ethical committee constituted conform Dutch law (BPRC Dier Experimenten Commissie, DEC) approved the research protocol (agreement number DEC\# 750) prior to the start and the experiments were all performed according to Dutch and European laws. The Council of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC International) has awarded BPRC full accreditation. Thus, BPRC is fully compliant with the international demands on animal studies and welfare as set forth by the European Council Directive 2010/63/EU, and Convention ETS 123, including the revised Appendix A as well as the 'Standard for humane care and use of Laboratory Animals by Foreign institutions' identification number A5539-01, provided by the Department of Health and Human Services of the United States of America's National Institutes of Health (NIH) and Dutch implementing legislation. The rhesus monkeys (*Macaca mulatta*, either gender, age 4--7 years, Indian or mixed origin) used in this study were captive-bred and socially housed. Animal housing was according to international guidelines for nonhuman primate care and use. Besides their standard feeding regime, and drinking water ad libitum via an automatic watering system, the animals followed an environmental enrichment program in which, next to permanent and rotating non-food enrichment, an item of food-enrichment was offered to the macaques daily. All animals were monitored daily for health and discomfort. All intravenous injections and large blood collections were performed under ketamine sedation, and all efforts were made to minimize suffering. Liver lobes were collected from monkeys that were euthanized in the course of unrelated studies (ethically approved by the BPRC DEC) or euthanized for medical reasons, as assessed by a veterinarian. Therefore, none of the animals from which liver lobes were derived were specifically used for this work, according to the 3Rrule thereby reducing the numbers of animals used. Euthanasia was performed under ketamine sedation (10 mg/kg) and was induced by intracardiac injection of euthasol 20%, containing pentobarbital.

*Macaca fascicularis* (cynomolgous monkeys) were used at the other facilities for the same purpose. Studies were approved by the SingHealth Institutional Animal Care And Use Committee (IACUC), Ref No.: 2015/SHS/1024, Novartis IACUC, protocol number 100280 and AFRIMS IACUC, Protocol Number PN13-06. AFRIMS, SingHealth and Novartis-LAS have full AAALAC accreditation.

*Plasmodium cynomolgi* sporozoite production and sporozoite isolation {#s4-2}
---------------------------------------------------------------------

*Macaca fascicularis* was infected with *P. cynomolgi bastianellii* (also known as strain B) sporozoites and blood stage parasitemia monitored by Giemsa stained smears. *Anopheles dirus* mosquito were directly fed on blood meal from the infected monkey. Salivary glands were collected 14--30 days post-mosquito infection. Infected mosquitoes salivary glands removal and sporozoite recovery was done as previously reported ([@bib11]). Sporozoites of *P. cynomolgi* were isolated from infected *A. dirus* salivary glands removed by hand dissection. Salivary glands were crushed in a potter; sporozoite form parasites were recovered after filtration through a 40 μm filter (Cell Strainer, Becton Dickinson) and a 3-min centrifugation at 4°C; 12 × 10^3^ rpm. *P. cynomolgi* infected *A. dirus* mosquitoes were obtained from the United States army medical directorate; armed forces research institute of medical sciences (AFRIMS) Bangkok 10400, Thailand. We have used *P. cynomolgi* M strain and *A. stephensi* for RNA-FISH experiments. Generation of *P. vivax* sporozoites, infection of huHep mice with *P. vivax* sporozoites and isolation of liver stages were carried out as described earlier ([@bib20]).

Simian primary hepatocyte culture conditions and sporozoite infection {#s4-3}
---------------------------------------------------------------------

The primary hepatocytes used in this study were freshly isolated from healthy *Macaca fascicularis* liver segments as previously described ([@bib29]). For each experiment, at day −1, frozen hepatocytes were first thawed directly in 37°C water bath and then transferred into 25 mL of a pre-warmed recovery Medium A (Life technologies, CM7000). Hepatocytes were spun down at 1500 rpm for 5 min. Media were removed and the cell pellet re-suspended into 8 mL of Medium B (hepatocytes plating medium containing William E without phenol red indicator, Life Technologies ref: A1217601, supplemented with Life technologies supplement Pack CM3000, Life technologies CM3000). Hepatocytes were seeded at a density 25 × 10^4^ cells per cm ([@bib2]) in collagen I coated plates 96 wells (Greiner bio One ref 655956) and 48-well (Nest Scientific 748001); then incubated in 37°C, 5% CO~2~ for overnight. At day-0, Medium C (William\'s E medium with phenol red indicator, Life Technologies ref: 12551--032, supplemented with 10% FetalCloneII serum, ref: SH30066.03, 5 × 10^−5^ M water-soluble hydrocortisone, sigma ref: H0396, 5 μg per ml insulin, 2 mM L-glutamine and 200 U per ml penicillin, 200 μg per ml streptomycin, Life Technologies) was used to wash away unattached cells and to maintain the culture. At day-0, *P. cynomolgi* freshly isolated sporozoites were re-suspended in the Medium C at 10^6^ sporozoites per mL. 6 × 10^4^ and 12 × 10^4^ sporozoites per well were inoculated into hepatocytes cultures in 96- and 48-well plates, respectively. To sediment parasite on the cells, infected culture plates were centrifuged for 10 min at 8°C, 2 × 10^3^ rpm. Cultures were then incubated at 37°C, 5% CO~2~ for 3 hr. At 3 hr post-infection, cultures were washed three times with Medium C and then maintained at 37°C, 5% CO~2~ in the same Medium C. For sandwich Matrigel cultures, Matrigel (BD Biosciences ref: 356234) was added as per the manufacturer\'s recommendations at day-0, 3 hr post-infection. To assess hepatic parasites growth kinetics and dynamics from day-0 to day-21, *P. cynomolgi* infected cultures were maintained in Medium C that was renewed every other day. For each defined time points, the cultures were ended by 100% cold methanol fixation for 3 min.

Drug evaluation against *P. cynomolgi* hepatic stages using LISP2 {#s4-4}
-----------------------------------------------------------------

PI4K inhibitor, KDU691 was synthesized as previously reported ([@bib19]) and all other compounds used in this study were procured from Sigma-Aldrich (St. Louis, MO). *P. cynomolgi* hepatic forms drug assessment was done as schematically shown in [Figure 4a](#fig4){ref-type="fig"} by treating culture from day 4 to day 8 with drugs renewed at day 6. At day 8, all drugs were removed by three consecutives washings and growth monitored for defined time points in medium C which was renewed every other day. Reference antimalarials which included non anti-relapsing compounds such as atovaquone (ATQ) (0.25 µM) and KDU691 (0.5 µM); the 8-aminoquinolines tafenoquine (TQ) (1 µM) and primaquine (PQ) (5 µM) that prevent relapse were used. These concentrations used were chosen for ATQ and KDU691 to selectively kill developing parasites (LISP2+ and LISP2++) and assess hypnozoite (LISP-) activation at the later days. For TQ and PQ, selected concentrations were to inhibit all liver stage parasites preventing later LISP2- parasites activation. All concentrations were selected based on compound dose response curves. Compounds IC~50~ were generated by treating cultures as above with three-fold dilution concentrations from 10 μM to 13 nM. For ATQ, the three-fold dilution concentration was from 5 μM to 6 nM. For IC~50~ generation, all cultures were ended at day 8 post-infection. One tail t test was used to assess the level of significant reduction of different hepatic forms due to drug treatment compared to DMSO treatment.

Assessment of cellular viability of simian primary hepatocytes under drug exposure {#s4-5}
----------------------------------------------------------------------------------

To evaluate compounds cytotoxicity against the primary hepatocytes, the cells were cultured without infection and exposed to 10 μM of each compound treatment as above from day 4 to day 8 with all drugs renewed at day 6. Puromycin (Pur) was included as positive control ([@bib4]) and DMSO as negative control during the drug exposure. To stop all cell metabolisms, five minutes of 100% methanol treatment was included at day 8. At day 8, cell counting kit-8 solution (CCK-8) was diluted 2.5-fold in complete Medium C and 70 µL of diluted CCK8 was added to each well of the plate containing 50 µL of Medium C. The plates were incubated for 3 hr at 37°C, 5% CO~2~. The absorbance at 450 nm was measured by Envision.

Parasite immuno-fluorescence assay (IFA) and RNA FISH {#s4-6}
-----------------------------------------------------

*P. cynomolgi* liver stages were detected with anti-*P. cynomolgi* HSP70 (PcyM_0515400) polyclonal antibody, anti-*P. cynomolgi* LISP2 (PcyM_0307500) monoclonal antibody, anti-H3K9ac monoclonal antibody (Abcam, ab177177) and anti-*P. cynomolgi* PV1 (PcyM_0933600) polyclonal antibody. The polyclonal and monoclonal antibodies used in our study were synthesized by Genscript. Briefly, using codon optimization and BacPowerTM bacterial protein expression technology, the selected epitopes were synthesized and used for immunization of animals as per Genscript established methods. Following 100% cold methanol fixation at the defined time points, *P. cynomolgi* cultures were first incubated for two hours at 37°C with the primary antibodies. Anti-*P. cynomolgi* HSP70 polyclonal antibody diluted 1:2000 in 1XPBS, anti-*P. cynomolgi* LISP2 monoclonal antibody diluted 1: 500 in 1XPBS, anti-H3K9ac monoclonal antibody diluted in 1:1000 in 1X PBS and anti-*P. cynomolgi* PV1 polyclonal antibody diluted 1: 500 in 1XPBS. Subsequently to 2 hr of incubation with these antibodies was followed by three washing with 1X PBS. To reveal hepatic stages parasites, cultures were then incubated with fluorescent secondary antibodies Alexa 488-conjugated goat anti-rabbit immunoglobulin (11034 Invitrogen) and Alexa 594-conjugated goat anti-mouse immunoglobulin and supplemented with 1 μg per ml of DAPI (Sigma) to stain parasites and cells nuclei for 1 hr. Secondary antibodies were removed by three washing with 1X PBS. Infected plates were kept with 1X PBS at 4°C for further parasite imaging and quantification. RNA-FISH was performed in the 96-well plates using the RNAscope Multiplex Fluorescent Assay v2 kit from Advanced Cell Diagnostics essentially according to the manufacturer's instructions. Following rehydration protease digestions were performed using pretreatment solution three from the kit at 1:10 dilution for 20 min at room temperature. Hybridizations were 2 hr at 40°C. Probes used were directed against *P. cynomolgi* HSP70 (PcyM_0515400, region 606--1837 of XM_004221103.1) and LISP2 (PcyM_0307500, region 2866--3853 of XM_004220801.1). After hybridization, TSA amplification steps were performed as described by the manufacturer. Following DAPI staining, cells were kept in PBS for imaging or immunofluorescence analysis. Images were acquired with a Leica DMI6000B inverted fluorescence microscope equipped with a DFC365FX camera using a HC PL APO 63x/1.40--0.60 oil objective. To evaluate specificity of RNA FISH signal, we have carried out RNAse A treatment before hybridization and we observe total loss of signal as compared to without RNAse A treatment (see [Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}). This negative control confirms the specificity of the LISP2 signal.

For visualization of *P. vivax* liver stages in huHep mouse livers, livers were harvested and fixed for 24 hr in 4% paraformaldehyde. Liver lobes were cut into 50 µm sections using a Vibratome apparatus (Ted Pella Inc, Redding, CA). For IFA, sections were permeabilized in Tris buffered saline (TBS) containing 3% H~2~0~2~ and 0.25% Triton X-100 for 30 min at room temperature. Sections were then blocked in TBS containing 5% dried milk at least 1 hr and incubated with primary antibody at 4°C overnight. *P. vivax* liver stages were detected with polyclonal LISP2 antibody (PVX_000975) (1:200) and monoclonal antibody specific for *P. vivax* UIS4 protein (PVX_001715) (1:500). Secondary antibodies were incubated for 2 hr at room temperature. Fluorescence images were acquired using an Olympus Delta Vision microscope equipped with deconvolution software.

Parasite imaging and quantification {#s4-7}
-----------------------------------

Enumeration of *P. cynomolgi* liver stage parasites was done under a fluorescence NIKON ECLIPSE TS100 microscope with a 40X magnification. Images were obtained from LEICA DM4000B. GraphPad Prism7 and Microsoft excel were used to generate all graph figure and dose response curves. ANOVA Statistical test was used to compare the compound toxicity to reference toxic compound Puromycin. The populations compared were from three independent biological replicates. A p value of 0.05 or less was considered to be statistically significant. Hepatic stages were measured in diameter (µm) as reported earlier ([@bib17]; [@bib34]).
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###### List of genes that were detected above \>10 FPKM (Fragments Per Kilobase per Million) in hypnozoite (727 genes) and that were in the top 5% genes expressed in schizonts (134 genes).

The data listed in the table derived from Voorberg et al, 2017. (Sz is schizont; three replicates and Hz is hypnozoite; four replicates)
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Reviewer

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for sending your article entitled \"The Plasmodium Liver-Specific Protein 2 (LISP2) is an early marker of liver stage development\" for peer review at *eLife*. Your article is being evaluated by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Gisela Storz as the Senior Editor.

Extensive discussion between the reviewers and editors led to a list of essential revisions, including new experiments, given below.

Essential revisions:

1\) In support of your claim, please address the question of antibody specificity experimentally to demonstrate that the protein is a marker for actively developing liver parasites. This experiment is needed as you only validated the specificity against recombinant antigen. While you provide IFA results, one suggestion would be to test the antibodies by western blots against cell lysates of infected hepatocytes.

2\) In view of the significance of the LISP2 as an earlier marker of reactivation, you need to show that reactivating cells become LISP2 positive prior to the increased abundance of other potential protein markers of active growth and/or metabolism.

3\) Normalize the staining intensity of H3K9 per nucleus.

4\) Reanalyze the microscopic images/samples using z stacks by 3D reconstruction as it would clearly distinguish LIPS1 localization.

5\) Revise the manuscript so that it reflects current status of *P. vivax* research.

6\) Correct some factual information as indicated by the reviewers.

7\) Include pertinent references such as Orito et al.

Reviewer \#1:

This is a strong manuscript and was clearly presented although there are a number of minor typographical errors. The authors describe a protein, LISP2, that appears to be a reliable marker of hypnozoite reactivation in liver stage malaria parasites. This is an exciting discovery since two human malaria species (*P. vivax* and *P. ovale*) produce dormant hypnozoites that can reactivate days or months later, greatly complicating malaria treatment and diagnosis. Although 8-aminoquinolines like primaquine and tafenoquine are active against hypnozoites, drug discovery of new compounds and compound classes would be facilitated by the discovery of a molecular marker able to discriminate between hypnozoites and similarly sized cells that are in the early stages of reactivation. The authors describe the discovery of LISP2 in a transcriptomic study of liver stage *P. cynomolgi* malaria parasites (a simian model for *P. vivax*) and examine LISP2 expression by IFA and FISH in a primary simian hepatocyte culture system. These data and particularly the quantitative analysis shown in Figure 3B make an excellent case for hynozoites remaining LISP2 negative until reactivation and similar phenomena are shown for *P. vivax* parasites in an in vivo humanized mouse infection system. Consistent with these findings, the authors show that LISP2 negative *P. cynomolgi* parasites (presumably hypnozoites) are sensitive to tafenoquine, but not to other antimalarial drugs. The drug susceptibility data in particular highlight the utility of LISP2 as marker for hypnozoite reactivation. For this purpose, it would be even better if LISP2 was actually a maker of hypnozoites rather than a marker of non-dormant parasites, but the authors state in their Introduction that transcriptomic studies have so far failed to identify a marker for the hypnozoites themselves. There is one area where the authors do not do a good job of highlighting their discovery. I would assume that a whole host of genes are expressed at high levels in metabolically active liver stage parasites compared to dormant hypnozoites. The significance of the LISP2 discovery would be that it is an earlier marker of reactivation. Can the authors show that reactivating cells become LISP2 positive prior to the increased abundance of other potential protein markers of active growth (enzymes of processes like glycolysis or nucleotide metabolism)?

Reviewer \#2:

This manuscript addresses the reactivation of dormant liver stages (hypnozoites) in the in vitro *P. cynomolgi* model as well as in in vivo (humanized mice) *P. vivax* model. Identification of markers distinguishing between arrested and developing liver stages is of great importance for the development of drugs targeting hypnozoites. Previous transcriptional profiling of small (early and dormant) and large (schizont) liver stages revealed that the lisp2 transcript is abundant in large stages and is also expressed in small stages. Remarkably, the lisp2 expression could distinguish three populations of *P. cynomolgi* liver stages, two of which were previously described -- 1) small dormant hypnozoites, 2) developing multinucleated liver schizonts and an additional new population of 3) small liver trophozoites in the process of reactivation. Similar results were obtained in *P. vivax*-infected humanized mice. The notion that LISP2 marks parasites that are actively developing in the liver is further supported by the selective drug susceptibility of these stages. The manuscript is written clearly, presented data are of good quality and conclusions are valid. The authors should address some spelling mistakes within the manuscript text.

There are a few weak points that should be addressed:

1\) While authors state that transcriptional activity is much weaker in dormant hypnozoites than in developing trophozoites, they only show H3K9Ac staining for hypnozoites and schizonts (not trophozoites) in Figure 3---figure supplement 2. This marker could be very useful to identify the point of reactivation (hypnozoite to trophozoite transition) and shed more light on whether the lisp2 expression indeed tightly correlates with this transition.

2\) All LISP2 detection was performed using staining with a single antibody (two antibodies for *P. cynomolgi* and *P. vivax*, respectively). These antibodies were raised against recombinant proteins corresponding to a part of the LISP2 protein. Importantly, the specificity of the antibodies was verified by western blots using the same recombinant proteins. To make sure that the native protein is specifically recognized, lysates of infected liver cells should be used for verification. Given the high LISP2 abundance, its detection should be possible despite the low amount of parasite material in the infected liver cells lysate.

3\) *P. berghei* LISP2 protein has been shown to be exported to the host cell cytoplasm and the nucleus (Morita et al., 2018), however, this does not seem to be the case for *P. cynomolgi* and *P. vivax* LISP2 in this study. Detection of LISP2 in infected liver cells by Western blot (as suggested in point 2) would additionally shed light on the processing of LISP2 in the liver stages of *P. cynomolgi* and allow to speculate on the causes of differential localization (while ruling out the option that the observed localization is an artefact based on cross-reactivity with other antigens).

4\) Antibody recognizing PV1 is not well characterized. Western blotting using lysates of infected liver cells (see point 2) should be used to verify its specificity.

5\) Authors speculate that LISP2 localizes to the parasitophorous vacuole or its extensions (cytoplasmic vacuoles) based on colocalization with PV1. However, the localization in most images resembles vesicles of the secretory pathway (which were also suggested for localization of both LISP2 in Morita et al., 2018 and PV1 (dense granules) in Chu, Lingelbach and Przyborski, 2011). Assuming that the antibody specifically stains LISP2 (see point 2), imaging of z-stacks followed by 3D reconstruction could shed more light on whether LISP2 truly localizes to the PV and its extensions or rather to isolated vesicles of the secretory pathway.

6\) Adding references to figures in the conclusions would, in my opinion, increase the clarity of the text for the reader.

Reviewer \#3:

LISP2 is a protein specifically expressed by plasmodial hepatic stages, required for the hepatic *P. berghei* merozoite formation. The manuscript entitled \"The Plasmodium Liver-Specific Protein 2 (LISP2) is an early marker of liver stage development\" shows that this protein is differentially expressed in uni-nucleated hypnozoites and growing hepatic trophozoites/schizonts, using two species of relapsing parasites (*P. vivax* and *P. cynomolgi*). Parasite stages were both defined/characterized morphologically and pharmacologically. This negative marker of hypnozoites and positive marker of growing liver stages can be used together with the parasite size and ploidy to discriminate these two populations, e.g., in anti-parasite/relapse drug-screening assays.

Introduction, first paragraph: *P. vivax* does not affect 2.5 billion people. Please revise.

Introduction, first paragraph: The argument that *P. vivax* research remains neglected does not seem to be justified based on the authors\' rational. According to the authors, *P. vivax* malaria represents only \~4% of the global malaria cases (8.5 M/ 219 M), which roughly matches the 5% of global investment. Please revise or better justify.

Subsection "LISP2 is an early marker of parasite development in the liver", first paragraph: Please cite the manuscript of Orito et al., 2013 after the mention of PbLISP2. The description of PbLISP2 localization and function is also missing.

Subsection "LISP2 is an early marker of parasite development in the liver", last paragraph: The way the phrase is constructed gives the impression that relapsing-plasmodial species have more similar LISP2 amino acid sequence when compared to other non-relapsing species. This does not seem to be the case, since the LISP2 of *P. ovale*, another relapsing-plasmodial species, has only 55% of AA identity with Pv LISP2 6-cys domain, while *P. coatneyi* and *P. knowlesi*, two non-relapsing parasites, have 76 and 74% of identity, respectively. This stronger similarity is probably due to their closer genetic origin than relapsing-capacity. Please rectify.

Subsection "LISP2 is an early marker of parasite development in the liver", last paragraph: Anti-Pv and Pc LISP2 antibodies were tested against the respective recombinant proteins used to generate them, but not against the respective parasites/ infected hepatocytes. Since the 6-cysteine domain is conserved among plasmodial proteins, it would be judicious to test the antibodies in a Western Blot using infected hepatocytes to assess the complexity of the antibody binding.

Subsection "LISP2 is an early marker of parasite development in the liver", last paragraph: What is the peripheral membrane? The parasitophorous vacuole membrane? It is not clear in the figures if LISP2 is colocalizing with UIS4, apart from the inset of Figure 2B (prominence).

Subsections "Assessment of LISP2 expression in *P. vivax* liver stages", "LISP2 expression differentiates dormant hypnozoites from developing liver stages", last paragraph and Discussion, second paragraph: LISP2- Hz and LISP2+ Tz does not seem to have identical size according to the Figure 3B and scheme of Figure 5 (\<8 days). Please apply a statistical analysis and clarify.

The authors state that \"schizonts were remarkably more transcriptional active than hypnozoites\" based on the number of H3K9ac structures. Since schizonts are multinucleated, a more informative way to strengthen this point would be to normalize the staining intensity of H3K9 per nucleus.

Subsection "LISP2 expression differentiates dormant hypnozoites from developing liver stages", last paragraph: Please justify the fact that LISP2- Hz and LISP2+ Tz are identical in size. Additionally, remove the \"only\" in the phrase since these two populations can apparently be distinguished based on the parasite size (Days 3-6), and also by the intensity (ploidy) of nuclear staining (please see the parasite nuclei in Figure 1---figure supplement 3). Please compare the intensity of the nuclear staining of LISP2- Hz and LISP2+ Tz and correct the scheme of Figure 5 accordingly.

Discussion, fifth paragraph: No data presented in the manuscript allows inferring the essentiality of LISP2 in the liver-stage development. Please remove \"essential\" from the phrase.

Figure 1---figure supplement 2 legend: At day 15, the pattern of LISP2 staining in the merged panel resembles the host cytoplasmic staining published by Orito et al., 2013. It would be important to confirm if Pv/Pc LISP2 is also exported to the cytoplasm/nucleus of the infected host cell.

10.7554/eLife.43362.033

Author response

> Essential revisions:
>
> 1\) In support of your claim, please address the question of antibody specificity experimentally to demonstrate that the protein is a marker for actively developing liver parasites. This experiment is needed as you only validated the specificity against recombinant antigen. While you provide IFA results, one suggestion would be to test the antibodies by western blots against cell lysates of infected hepatocytes.
>
> 2\) In view of the significance of the LISP2 as an earlier marker of reactivation, you need to show that reactivating cells become LISP2 positive prior to the increased abundance of other potential protein markers of active growth and/or metabolism.
>
> 3\) Normalize the staining intensity of H3K9 per nucleus.
>
> 4\) Reanalyze the microscopic images/samples using z stacks by 3D reconstruction as it would clearly distinguish LIPS1 localization.
>
> 5\) Revise the manuscript so that it reflects current status of P. vivax research.
>
> 6\) Correct some factual information as indicated by the reviewers.
>
> 7\) Include pertinent references such as Orito et al.
>
> Reviewer \#1:
>
> This is a strong manuscript and was clearly presented although there are a number of minor typographical errors. The authors describe a protein, LISP2, that appears to be a reliable marker of hypnozoite reactivation in liver stage malaria parasites. This is an exciting discovery since two human malaria species (P. vivax and P. ovale) produce dormant hypnozoites that can reactivate days or months later, greatly complicating malaria treatment and diagnosis. Although 8-aminoquinolines like primaquine and tafenoquine are active against hypnozoites, drug discovery of new compounds and compound classes would be facilitated by the discovery of a molecular marker able to discriminate between hypnozoites and similarly sized cells that are in the early stages of reactivation. The authors describe the discovery of LISP2 in a transcriptomic study of liver stage P. cynomolgi malaria parasites (a simian model for P. vivax) and examine LISP2 expression by IFA and FISH in a primary simian hepatocyte culture system. These data and particularly the quantitative analysis shown in Figure 3B make an excellent case for hynozoites remaining LISP2 negative until reactivation and similar phenomena are shown for P. vivax parasites in an in vivo humanized mouse infection system. Consistent with these findings, the authors show that LISP2 negative P. cynomolgi parasites (presumably hypnozoites) are sensitive to tafenoquine, but not to other antimalarial drugs. The drug susceptibility data in particular highlight the utility of LISP2 as marker for hypnozoite reactivation. For this purpose, it would be even better if LISP2 was actually a maker of hypnozoites rather than a marker of non-dormant parasites, but the authors state in their Introduction that transcriptomic studies have so far failed to identify a marker for the hypnozoites themselves. There is one area where the authors do not do a good job of highlighting their discovery. I would assume that a whole host of genes are expressed at high levels in metabolically active liver stage parasites compared to dormant hypnozoites. The significance of the LISP2 discovery would be that it is an earlier marker of reactivation. Can the authors show that reactivating cells become LISP2 positive prior to the increased abundance of other potential protein markers of active growth (enzymes of processes like glycolysis or nucleotide metabolism)?

We agree with the reviewer that demonstrating that, LISP2 expression precedes the expression of a late liver schizont specific protein that is not expressed in the hypnozoite, would add value to our findings. We have tried to generate antibodies against such proteins with limited success so far and the PV1 antibodies reported here is the result of those efforts. The Ferredoxin antibodies we have previously reported (Voorberg et al., 2017) were made in mouse, like the LISP2 antibodies, which unfortunately precludes double staining IFA experiments. Nonetheless, we would like to point out that in these experiments we have not observed expression of Ferredoxin in the early developing liver-stage forms in an expression pattern that is consistent with the LISP2 expression we report here. Although we agree that only double staining could unambiguously prove this point, our data seem to suggest that indeed LISP2 expression precedes Ferredoxin protein expression in liver schizonts. Unfortunately, to our knowledge, there are no other available *P. cynomolgi* (or *P. vivax*) specific antibodies that would allow us to make such a statement more definitively. We will certainly try to address this question as soon as such reagents would become available.

> Reviewer \#2:
>
> This manuscript addresses the reactivation of dormant liver stages (hypnozoites) in the in vitro P. cynomolgi model as well as in in vivo (humanized mice) P. vivax model. Identification of markers distinguishing between arrested and developing liver stages is of great importance for the development of drugs targeting hypnozoites. Previous transcriptional profiling of small (early and dormant) and large (schizont) liver stages revealed that the lisp2 transcript is abundant in large stages and is also expressed in small stages. Remarkably, the lisp2 expression could distinguish three populations of P. cynomolgi liver stages, two of which were previously described -- 1) small dormant hypnozoites, 2) developing multinucleated liver schizonts and an additional new population of 3) small liver trophozoites in the process of reactivation. Similar results were obtained in P. vivax-infected humanized mice. The notion that LISP2 marks parasites that are actively developing in the liver is further supported by the selective drug susceptibility of these stages. The manuscript is written clearly, presented data are of good quality and conclusions are valid. The authors should address some spelling mistakes within the manuscript text.

We believe we have addressed all major concerns raised by this reviewer including grammatical errors in the revised manuscript.

> There are a few weak points that should be addressed:
>
> 1\) While authors state that transcriptional activity is much weaker in dormant hypnozoites than in developing trophozoites, they only show H3K9Ac staining for hypnozoites and schizonts (not trophozoites) in Figure 3---figure supplement 2. This marker could be very useful to identify the point of reactivation (hypnozoite to trophozoite transition) and shed more light on whether the lisp2 expression indeed tightly correlates with this transition.

We thank the reviewer for this useful request for clarification. We do not suggest that H3K9 allows for the quantitative assessment of transcriptional activity across liver-stages and our statement regarding the lower transcriptional activity of hypnozoites is solely based on our previously reported transcriptomic analysis (Voorberg et al., 2017 and Bertschi et al. 2018). We nonetheless carried out additional experiments and included H3K9ac and LISP2 co-staining for all liver-stages (i.e. Hz, Tz and Sz) so the reader can more directly appreciate the relative distribution and level of expression of H3K9ac and LISP2 throughout the development of the parasite. See revised Figure 3---figure supplement 2.

Additional reference:

> Bertschi NL, et al. Transcriptomic analysis reveals reduced transcriptional activity in the malaria parasite Plasmodium cynomolgi during progression into dormancy. eLife 7, e41081 (2018).
>
> 2\) All LISP2 detection was performed using staining with a single antibody (two antibodies for P. cynomolgi and P. vivax, respectively). These antibodies were raised against recombinant proteins corresponding to a part of the LISP2 protein. Importantly, the specificity of the antibodies was verified by western blots using the same recombinant proteins. To make sure that the native protein is specifically recognized, lysates of infected liver cells should be used for verification. Given the high LISP2 abundance, its detection should be possible despite the low amount of parasite material in the infected liver cells lysate.

We assessed specificity of LISP2 in infected hepatocyte lysate and uninfected lysate by western blot. Since *P. cynomolgi* LISP2 is a high molecular weight protein (270Kda), day 8 infected samples were tested in two different lysis condition (denaturing and non-ionic cell lysis condition). In order to visualize the separation of high molecular weight LISP2, we subjected infected and uninfected lysates with Tris acetate SDS-PAGE and performed western blot (see [Author response image 1](#respfig1){ref-type="fig"}). Under both denaturing and non-ionic lysis (data not shown) conditions, we were unable to detect any protein bands in both infected and uninfected samples. Similarly, we also did not obtain any protein band when we subjected lysates under Tris glycine SDS-PAGE. Additionally, we attempted to enrich the samples through immunoprecipitation experiments with LISP2 antibody prior to western blot analysis. However, we could not detect LISP2 protein or any other protein band in these experiments (data not shown).

We have included two positive controls for western and both worked well. We could detect the recombinant LISP2 epitope (37Kda) that was used to generate the anti-LISP2 antibody. In addition, we could also detect specific bands of the expected size for tubulin with anti-tubulin antibodies.

![](elife-43362-resp-fig1){#respfig1}

Given, the low infection rate (0.4%), we anticipated that, as mentioned by the reviewer, it would be difficult to detect LISP2 protein by western blot. However, the very low background observed in these experiments in uninfected/infected cells confirm that the anti-LISP2 antibodies are quite specific.

Moreover, RNA-FISH data with LISP2 probe (Figure 1---figure supplement 4) reveals the similar localization pattern observed with anti-LISP2 antibody in hypnozoites, trophozoites and schizonts. Taken together, the IFA data, RNA FISH data and western blot data corroborate the specificity of the anti-LISP2 antibody.

> 3\) P. berghei LISP2 protein has been shown to be exported to the host cell cytoplasm and the nucleus (Morita et al., 2018), however, this does not seem to be the case for P. cynomolgi and P. vivax LISP2 in this study. Detection of LISP2 in infected liver cells by Western blot (as suggested in point 2) would additionally shed light on the processing of LISP2 in the liver stages of P. cynomolgi and allow to speculate on the causes of differential localization (while ruling out the option that the observed localization is an artefact based on cross-reactivity with other antigens).

We thank the reviewer for this question. We also investigated this previously and carried out extensive immunofluorescence microscopy from day 1 to day 21 post infection in vitro (Figure 1). We did not observe any LISP2 protein in hepatocytes at any time points. Additionally, we corroborated the absence of LISP2 protein in the host cell in a different relapsing model, *P. vivax* (Figure 2). Given the significant divergence in amino-acids sequences between *P. cynomolgi* and *P. berghei* LISP2 proteins, we cannot speculate whether LISP2 in *P. cynomolgi* is also proteolytically processed and we failed to detect LISP2 in western blot experiments.

> 4\) Antibody recognizing PV1 is not well characterized. Western blotting using lysates of infected liver cells (see point 2) should be used to verify its specificity.

As mentioned above, due to low infection rate (0.4%), we could not detect LISP2 in infected and uninfected lysates. We also tried PV1 antibodies and likewise failed to see any specific bands.

> 5\) Authors speculate that LISP2 localizes to the parasitophorous vacuole or its extensions (cytoplasmic vacuoles) based on colocalization with PV1. However, the localization in most images resembles vesicles of the secretory pathway (which were also suggested for localization of both LISP2 in Morita et al., 2018 and PV1 (dense granules) in Gupta et al.,2016). Assuming that the antibody specifically stains LISP2 (see point 2), imaging of z-stacks followed by 3D reconstruction could shed more light on whether LISP2 truly localizes to the PV and its extensions or rather to isolated vesicles of the secretory pathway.

To answer these questions, day 6 infected hepatocytes co-stained with PV1 and LISP2. 30-40 stacks of images were acquired with 100X objective lens with Z-step size of 1 μm. Three-Dimensional images were reconstructed using deconvoluted z-stack images. In the revised manuscript, we have incorporated 3-D videos of individual localization of nuclear stain, LISP2 and PV1 in mature schizonts.

Video 2 is the 3-D video of multinucleate schizont co-stained with LIPS2 and PV1.

PV1 is a known marker of parasitophorous vacuole. In blood stages, PV1 stains the parasite in circumferential pattern surrounding the parasite and described as ring of beads in Chu, Lingelbach and Przyborsk, 2011.

Our results recapitulate similar observations in hepatic stages and substantiate that LISP2 co-localizes with PV1 marker and stains the parasitophorous vacuolar membrane structures also shown in additional images in Figure 3---figure supplement 3.

Nonetheless, we do agree with the reviewer that it would be important to explore the vacuolar structures that resemble secretory vesicles. We will continue to investigate this question and to report our results as we are finding out more.

See Video 2, 3, 4 and 5 and Figure 3---figure supplement 3.

> 6\) Adding references to figures in the conclusions would, in my opinion, increase the clarity of the text for the reader.

We incorporated those suggestions in the revised manuscript. See revised figure legends.

> Reviewer \#3:
>
> LISP2 is a protein specifically expressed by plasmodial hepatic stages, required for the hepatic P. berghei merozoite formation. The manuscript entitled \"The Plasmodium Liver-Specific Protein 2 (LISP2) is an early marker of liver stage development\" shows that this protein is differentially expressed in uni-nucleated hypnozoites and growing hepatic trophozoites/schizonts, using two species of relapsing parasites (P. vivax and P. cynomolgi). Parasite stages were both defined/characterized morphologically and pharmacologically. This negative marker of hypnozoites and positive marker of growing liver stages can be used together with the parasite size and ploidy to discriminate these two populations, e.g., in anti-parasite/relapse drug-screening assays.
>
> Introduction, first paragraph: P. vivax does not affect 2.5 billion people. Please revise.

We have changed the sentence as follows:

"*P. vivax* is the second most prevalent malarial pathogen, with a wider geographical distribution than *P. falciparum*, suggested to be a risk of malaria infection for 2.5 billion people."

> Introduction, first paragraph: The argument that P. vivax research remains neglected does not seem to be justified based on the authors\' rational. According to the authors, P. vivax malaria represents only \~4% of the global malaria cases (8.5 M/ 219 M), which roughly matches the 5% of global investment. Please revise or better justify.

We thank the reviewer for this clarification and have thus revised the sentence as follows:

"Despite its high prevalence in many malaria endemic countries, *P. vivax* research is restricted to few laboratories and limited progress have been made."

> Subsection "LISP2 is an early marker of parasite development in the liver", first paragraph: Please cite the manuscript of Orito et al., 2013 after the mention of PbLISP2. The description of PbLISP2 localization and function is also missing.

We have made the requested changes in the first paragraph of the subsection "LISP2 is an early marker of parasite development in the liver".

> Subsection "LISP2 is an early marker of parasite development in the liver", last paragraph: The way the phrase is constructed gives the impression that relapsing-plasmodial species have more similar LISP2 amino acid sequence when compared to other non-relapsing species. This does not seem to be the case, since the LISP2 of P. ovale, another relapsing-plasmodial species, has only 55% of AA identity with Pv LISP2 6-cys domain, while P. coatneyi and P. knowlesi, two non-relapsing parasites, have 76 and 74% of identity, respectively. This stronger similarity is probably due to their closer genetic origin than relapsing-capacity. Please rectify.

We thank the reviewer for drawing our attention to this point.

We agree with that the 6-cys domain is highly conserved across *Plasmodium* orthologs and we have thus removed this sentence to avoid the possible confusion highlighted by the reviewer.

> Subsection "LISP2 is an early marker of parasite development in the liver", last paragraph: Anti-Pv and Pc LISP2 antibodies were tested against the respective recombinant proteins used to generate them, but not against the respective parasites/ infected hepatocytes. Since the 6-cysteine domain is conserved among plasmodial proteins, it would be judicious to test the antibodies in a Western Blot using infected hepatocytes to assess the complexity of the antibody binding.

See response to reviewer 2 point 2.

> Subsection "LISP2 is an early marker of parasite development in the liver", last paragraph: What is the peripheral membrane? The parasitophorous vacuole membrane? It is not clear in the figures if LISP2 is colocalizing with UIS4, apart from the inset of Figure 2B (prominence).

Here the peripheral membrane represents LISP2 staining around the parasite body in a circumferential manner. We later showed co-localization of LISP2 with PV1, a parasitophorous vacuole marker (Figure 3C).

We observed only partial overlap of LISP2 and UIS4 at the so-called prominence as seen in Figure 2B. In developing stages, these two proteins do not overlap as shown in Figure 2A.

> Subsections "Assessment of LISP2 expression in P. vivax liver stages", "LISP2 expression differentiates dormant hypnozoites from developing liver stages", last paragraph and Discussion, second paragraph: LISP2- Hz and LISP2+ Tz does not seem to have identical size according to the Figure 3B and scheme of Figure 5 (\<8days). Please apply a statistical analysis and clarify.

Here, we meant to say that these two parasite populations' sizes range similarly. We apologies for this confusion. In the updated manuscript, we have amended the sentences accordingly to clarify this point (subsection "Assessment of LISP2 expression in *P. vivax* liver stages", subsection "LISP2 expression differentiates dormant hypnozoites from developing liver stages", last paragraph and Discussion, second paragraph).

> The authors state that \"schizonts were remarkably more transcriptional active than hypnozoites\" based on the number of H3K9ac structures. Since schizonts are multinucleated, a more informative way to strengthen this point would be to normalize the staining intensity of H3K9 per nucleus.

As stated earlier in response to reviewer 2 (point 1), we do not suggest that H3K9 allows for the quantitative assessment of transcriptional activity across liver-stages and our statement regarding the lower transcriptional activity of hypnozoites is based on our previously reported transcriptomic analysis (Voorberg et al., 2017 and Bertschi et al. 2018). Thus we not believe that a normalization of the signal is warranted at this stage. Nevertheless, in the revised figure (Figure 3---figure supplement 2), we provided additional images of all three liver-stages (i.e. Hz, Tz and Sz) which allows for the visual resolution of individual nuclei so the reader can directly compare the distribution and expression of this marker across the development of the parasite in the liver. We also reconstructed 3-D images of schizonts using de-convoluted Z stack images co-stained with H3K9ac and LISP2. These Z stacks clearly showed LISP2 staining surrounding the cellular body in a circumferential pattern while H3K9ac localized to what appears to be individual nuclear structures within schizonts. In the revised manuscript, we have included this additional video (see Video 1).

> Subsection "LISP2 expression differentiates dormant hypnozoites from developing liver stages", last paragraph: Please justify the fact that LISP2- Hz and LISP2+ Tz are identical in size. Additionally, remove the \"only\" in the phrase since these two populations can apparently be distinguished based on the parasite size (Days 3-6), and also by the intensity (ploidy) of nuclear staining (please see the parasite nuclei in Figure 1---figure supplement 3). Please compare the intensity of the nuclear staining of LISP2- Hz and LISP2+ Tz and correct the scheme of Figure 5 accordingly.

See our seventh response to reviewer 3 (above). We have clarified throughout the similarity in size ranges throughout the manuscript and modified the sentence as suggested to remove the word "only".

Unfortunately, as previously reported for *P. vivax* hypnozoites (March et al., 2013), DAPI staining does not allow for an accurate and quantitative assessment of ploidy.

We believe that with the above clarifications no changes to Figure 5 are warranted.

> Discussion, fifth paragraph: No data presented in the manuscript allows inferring the essentiality of LISP2 in the liver-stage development. Please remove \"essential\" from the phrase.

We have updated the text as suggested (Discussion, fourth paragraph).

> Figure 1---figure supplement 2 legend: At day 15, the pattern of LISP2 staining in the merged panel resembles the host cytoplasmic staining published by Orito et al., 2013. It would be important to confirm if Pv/Pc LISP2 is also exported to the cytoplasm/nucleus of the infected host cell.

We do not believe that we provided any evidence suggesting that the Pc LISP2 protein is exported to the host cell cytosol using the antibodies we raised against the 6-cys domain of the protein. We would also like to point out that we unsuccessfully attempted to raise antibodies against the Pc LISP2 N-terminal region which was shown to be exported to the hepatocyte cytosol in *P. berghei* parasites.

See also our response to reviewer 2 point 3.

[^1]: These authors contributed equally to this work.
